Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.

Sheng-Yuan WangChing-Han LaiChian-Wei ChenSzu-Chun YangChao-Chun ChangChia-Ying LinYi-Ting YenYau-Lin TsengPo-Lan Su Chien-Chung Lin Wu-Chou Su

Published in: Thoracic cancer (2021)

This current study suggests that EGFR-TKIs is a better choice for patients with unresectable stage III EGFR-mutant adenocarcinoma. However, further randomized studies are required to validate the results.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
locally advanced
squamous cell carcinoma
double blind
open label
rectal cancer
clinical trial
phase ii
free survival
placebo controlled